<DOC>
	<DOCNO>NCT02608905</DOCNO>
	<brief_summary>Sodium-glucose cotransporter 2 ( SGLT-2 ) inhibitor reduce hyperglycemia improve peripheral insulin sensitivity ameliorate glucotoxicity . Insulin resistance type 2 diabetes ( T2DM ) associate endothelial dysfunction vascular inflammation . Thus strategy improve insulin sensitivity low glucotoxicity may improve endothelial inflammation vascular inflammation . However , effect agent vascular inflammation endothelial function know patient type 2 diabetes although anti-inflammatory property demonstrate various animal model . In present study investigator assess dapagliflozin treatment 12 week decrease monocyte inflammation improve endothelial function patient type 2 diabetes metformin monotherapy .</brief_summary>
	<brief_title>Effect Dapagliflozin Inflammation Endothelial Function</brief_title>
	<detailed_description>The insulin-resistant state type 2 diabetes mellitus ( T2DM ) largely mediated inflammatory pathway affect skeletal muscle primary site whole body insulin resistance . Nuclear factor kappa B ( NFkappaB ) regulate pro-inflammatory cytokine ultimately impair skeletal muscle insulin signal fatty acid oxidation ; activity reflect overall inflammatory tone skeletal muscle . Recent human study confirm NFkappaB elevate skeletal muscle T2DM human subject . Furthermore , inflammatory process signal impairment contribute worsen endothelial dysfunction , independent predictor future cardiovascular event T2DM . In addition , SGLT-2 Inhibitors reduce body weight , visceral adiposity , systolic diastolic blood pressure , microalbuminuria , oxidative stress . However , study examine effect SGLT-2 inhibitor therapy NFkappaB inflammatory mediator human T2DM . Moreover , study examine effect SGLT-2 inhibitor therapy endothelial function population . In present study investigator assess whether dapagliflozin treatment 12 week reduce monocyte inflammation improve endothelial dysfunction patient type 2 diabetes metformin monotherapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Men woman , age 21 70 year . ) Women childbearing potential must use acceptable method contraception avoid pregnancy throughout study manner risk pregnancy minimize . ii ) Women must pregnant breastfeeding . 3 . Patients Type 2 Diabetes Mellitus follow parameter study entry : hemoglobin A1c range 7.0 % 9.0 % fast blood glucose less equal 200 mg/dL . 4 . Patients must stable dose Metformin therapy 3 month ; dose metformin change duration study . 5 . Patients allow , require , statin , Angiotensin Converting Enzyme ( ACE ) inhibitor , angiotensinreceptor blocker dose stable least last 3 month prior enrollment study . Doses change duration study . 6 . Patients must Body Mass Index 2735 kg/m2 7 . Patients must stable body weight three month prior enrollment study . 8 . Patients must Creatinine Clearance great 60 mL/min ( calculate CockcroftGault formula ) . 9 . Patients must Hematocrit great equal 34 % ; Serum creatinine less than1.5 mg/dl men 1.4 mg/dl woman Creatinine Clearance great 60 ml/min ; serum aspartate aminotransferase ( AST ) less 2.5 time upper limit normal , serum alanine transaminase ( ALT ) less 2.5 time upper limit normal , serum alkaline phosphatase less 2.5 time upper limit normal . 1 . History Type 1 diabetes mellitus 2 . Women pregnant breastfeed 3 . Patients receive lipidlowering medication statin within last 3 month . 4 . Patient receive SGLT2 inhibitor , incretin therapy , dipeptidyl peptidase 4 ( DPP4 ) inhibitor , thiazolidinediones , insulin , sulfonylurea , alphaglucosidase inhibitor , corticosteroid , immunosuppressive therapy , thiazide loop diuretic , hormone replacement therapy within last 3 month . 5 . Patient must stop treatment nonsteroidal antiinflammatory drug ( NSAID ) antioxidant vitamin supplement least one week prior start study 6 . Patients diabetic gastroparesis . 7 . Patients current tobacco use . 8 . Patients active malignancy . 9 . Patients history urinary bladder cancer 10 . Patients history clinically significant heart disease , peripheral vascular disease , pulmonary disease study 11 . Subjects history serious hypersensitivity reaction dapagliflozin . 12 . Prisoners , subject involuntarily incarcerate . 13 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness . 14 . Patients significant cardiac , hepatic renal disease ( Creatinine Clearance less 60 mL/min calculate CockcroftGault formula ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>